Home / News

Lupin Q2 Revenue Beats Forecasts Despite Profitability Pressures

• Lupin's Q2 FY27 revenue of ₹7,827 crore exceeded analyst expectations, rising 11% year-on-year but declining 5.4% sequentially. • The company's US market, its largest, contributed 39% of sales with revenue of $317 million, surpassing estimates of $290-292 million. • Profitability metrics contracted sharply, with EBITDA falling 13% YoY and net profit declining 22% to ₹1,155 crore. • Lupin shares traded 2% higher on Wednesday; the stock had closed at ₹2,015.90 on Tuesday and is down about 4% in 2026.

Pharmaceutical major Lupin Ltd. reported a mixed financial performance for the second quarter of fiscal year 2027, with revenues surpassing market estimates amid significant pressure on profitability. The company's shares traded with gains following the earnings release, reflecting investor focus on the top-line beat despite weaker margins. For the quarter ending September 30, Lupin posted revenue of ₹7,827.26 crore, marking an 11% increase from the ₹7,047.51 crore reported in the same period last year. While this figure came in slightly above analyst poll estimates of ₹7,779.6 crore, it represented a sequential decline of 5.4% from the previous quarter's ₹8,276.89 crore. The company's earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 13% year-on-year to ₹2,044.41 crore, leading to a margin contraction to 26.1%. This compares to an EBITDA margin of 33.2% in Q2 FY26 and 29.6% in Q1 FY27. Net profit saw a steeper decline of 22% year-on-year, settling at ₹1,155.3 crore. However, both EBITDA and net profit exceeded consensus forecasts by approximately 9% and 10%, respectively. Geographically, the United States remained Lupin's dominant market, contributing 39% to total sales and generating revenue of $317 million, which comfortably exceeded the projected range of $290-292 million. The domestic Indian market, accounting for 31% of sales, showed resilience with a 14.7% year-on-year revenue increase to ₹2,383.6 crore. Other developed markets grew 45.7% year-on-year to ₹1,182.3 crore, while emerging markets revenue declined 3.5% to ₹890.8 crore. Lupin shares had ended 0.97% higher at ₹2,015.90 on Tuesday, November 3, and the stock is down around 4% so far in 2026.